Download - Lundbeck

LUNDBECK
MAGAZINE
2007
2. edition

Lundbeck Magazine 2007
CONTENTS
The brain
At only 1.35 kg and accounting for less than 2%
of our body weight, the brain is the seat of our
intelligence, interpreter of our senses, initiator
of body movements, controller of behaviour,
and expresser of our mood. Nestled in a bony
encasement and awash with protective fluid,
the brain is the source of all the qualities that
define our humanity. Page 4
Read about:
Hard choices Page 12
The causes of depression Page 18
Knowledge obliges Page 30
The world did not come to an end
My name is Hans-Jürgen Cosmo. I was diagnosed with
Parkinson’s disease in 199 6 when I was 56 years old.
Read the whole story on page 16
Education as a passion
My name is André Joubert, and I am a
psychiatrist the Lundbeck Institute. Since
the Institute was founded in 1997 we have
educated psychiatrists, neurologists and
other mental health care workers.
Read more on page 24
Healthy and safe environment
My name is Camilla Ransfort. I am head of
section in the Health and Safety Department.
My job is to ensure that Lundbeck’s
employees work under conditions that
promote their health and safety. Page 28
THE KEY WORD IS DEVELOPMENT
My name is Pil Soo Oh, and I am the
Managing Director of Lundbeck Korea.
During recent years, the market in
Korea has grown due to economic
development as well as a greater
openness regarding depression. Page 22

3
Welcome
to Lundbeck
We are a company with 5300 employees who all work to
develop, manufacture and market drugs for treating disorders
of the central nervous system.
According to WHO, more than 700 million cases of CNS disorders
are reported annually around the world. Lundbeck was
among the pioneers who 50 years ago first enabled doctors to
treat disorders such as schizophrenia and depression. However,
despite persevering research efforts, there are still patients who
cannot yet receive optimal treatment. The motivating force in
our work is one day to be able to help these persons.
While our origins are in Denmark, Lundbeck works throughout
the entire world. Our drugs are available in more than 90
countries, and Lundbeck is represented in 58 of them.
I hope this magazine will provide food for thought, as well as
an impression of our company, our work, and who we are.
At Lundbeck, we focus on people; we develop and market highly
specialized drugs, and we are sufficiently ambitious to aim at
being among the best in our field. This requires extremely skilled
employees who have both empathy and commitment. During
the coming years, we hope to be able to contribute new drugs
for the treatment of stroke, alcohol dependence, depression and
schizophrenia.
Yours sincerely
Claus Bræstrup
President & CEO
H. Lundbeck A/S
Corporate Reporting
Design: Bysted A/S
Photo; Lars Bech and Nicky Bonne
Illustration: Nis Nielsen
Text: Claudia Knauer: The world did not come to an end
Print: Quickly Tryk A/S
2. edition, April 2007

4
The Lundbeck Magazine 2007
ThE Brain
At only 1.35 kg and accounting for less than 2% of our body weight, the brain is the
seat of our intelligence, interpreter of our senses, initiator of body movements,
controller of behaviour, and expresser of our mood. Nestled in a bony encasement
and awash with protective fluid, the brain is the source of all the qualities that define
our humanity.
The cerebrum
The cerebellum
The midbrain
The brainstem

5
For centuries, scientists and philosophers
have been fascinated by
the brain. Despite their horror of
dissecting people, the ancient
Greeks offered an opinion in which
the heart served as the seat of reason and the
brain simply “tempered the heat and seething
of the heart”.
In 1600, the young English doctor, William Harvey
(1578-1657), studying at Padua University in
Italy, reported his discovery that the “heart
sends blood through the body in a loop” and
functioned basically as a pump. This resulted in
philosophical shock waves.
In Oxford, one of his students, Thomas Willis
(1621-1675), was first to track the flow of
blood from the heart to the brain. He gave
the first account of the network of nerves and
blood vessels on which our understanding of
the brain is based; the brain’s role in the control
of the function of many other organs.
Detailed mapping of the brain began in the
nineteenth century with the observations of
the French physician Pierre Paul Broca (1824-
1880) and of the German psychiatrist Karl
Wernicke (1848-1905), whose names have
been given to the brain’s speech centres. They
established that deterioration of specific
mental aptitudes, such as speech, or musical
memory, could be related to strictly localized
cerebral lesions.
The architecture of the brain
The brain consists of several main structures,
primarily the cerebrum, the midbrain, cerebellum
and the brainstem.
The cerebrum
The largest section of the brain is the cerebrum
– the most highly developed part of the human
brain. The cerebrum is split into two hemispheres
by a deep fissure. Despite this split, the two
cerebral hemispheres communicate with each
other comprehensively through thick tracts of
nerve fibres that lie at the base of this fissure.
Although the two hemispheres seem physically
to be mirror images of each other, they are very
different in their function. For instance, the
ability to form words seems to lie primarily in
the left hemisphere, while the right hemisphere
seems to control many abstract reasoning skills.
For some as yet unknown reason, most nerve
tracts cross over from left to right, or right to
left on their route from the brain to the body,
and vice versa. Therefore, the right cerebral
hemisphere primarily controls the left side of the
body and the left hemisphere primarily the right
side. When one side of the brain is damaged, the
opposite side of the body is affected. Therefore,
a stroke in the left hemisphere of the brain may
leave the right arm and leg paralysed and the
person may have an inability to speak.
Each cerebral hemisphere is divided into
sections, or lobes, each of which specializes in
different functions. The two frontal lobes, left
and right, which lie directly behind the forehead,
are used for planning, imagination, reasoning
and arguments. The frontal lobes seem to
provide our ability to keep one idea in mind
while other ideas are considered by acting as a
short-term memory storage site. Toward the
rear portion of each frontal lobe is a motor area
where control of voluntary movement occurs.
On the left frontal lobe is Broca’s speech area
which allows thoughts to be transformed into
words.
Behind the frontal lobes lie the parietal lobes.
The front sections of these lobes, which lie just
behind the motor areas, are the primary sensory
areas. These areas receive information about
temperature, taste, touch and movement from
the rest of the body. Reading and arithmetic
are also functions of the parietal lobe.
The two lobes at the back of the brain are
called the occipital lobes. Here the visual
image from the eyes is processed and links to
previous images stored in memory. Damage
to the occipital lobes can cause blindness.
On the outer left and right sides of the
cerebrum lie the temporal lobes, which lie in
front of the visual areas and nest under the
parietal and frontal lobes. Appreciation of
music occurs in these lobes as at the top of
each temporal lobe is an area responsible for
receiving information from the ears. The
underside of each temporal lobe plays a crucial
role in forming and retrieving memories,
including those associated with music and
smell. Other parts of these lobes seem to
integrate memories and sensations of taste,
smell, sound, sight and touch.
The midbrain
Beneath the cerebral lobes, deep within the two
hemispheres, lie several structures that make
up the midbrain, the gatekeepers between the
cerebral hemispheres above and the spinal cord
and the rest of the body, below. The midbrain
structures, like the lobes in the cerebral hemispheres,
come in pairs; each is duplicated in the
opposite half of the brain. These structures not
only determine our emotional state, they also
modify our perceptions and responses depending
on that state, and allow the initiation of movements
which are made without thinking.
Vegetative functions, such as sleep and appetite,
are controlled by the midbrain structures.
The hypothalamus, which is about the size of a
pea, directs a multitude of important functions.
It controls, among others, the sleep-wake cycle,
and the release of adrenaline in stress or danger
situations. The hypothalamus also has an
important emotional control over feelings such
as exhilaration, anger or sadness. Close to the
hypothalamus lies the thalamus, a major
integrator of information going between the
spinal cord and the cerebrum. An arching tract
of neurons leads from the hypothalamus and
the thalamus to the hippocampus which acts
as a memory indexer, sending memories to the
appropriate part of the cerebral hemisphere for
long-term memory retention and retrieval. The
basal ganglia are clusters of neurons surrounding
the thalamus which are responsible for initiating
and integrating movements.

6
The Lundbeck Magazine 2007
The Brain
Parkinson’s disease, with symptoms such as
tremors, rigidity, and a stiff, shuffling walk, is a
neuronal disease in the basal ganglia.
The cerebellum
Below the base of the brain, toward the back,
lies the cerebellum, often called the “tree of
life”. The cerebellum controls the body’s vital
functions such as respiration and heart rate,
maintains balance and coordinates fine motor
movements and learned repetitive movements.
When playing the piano or hitting a tennis ball,
one activates the cerebellum.
The brainstem
From the base of the midbrain projects the
brainstem, the connection between the cerebrum,
the cerebellum and the spinal cord. The
brainstem controls some reflex actions and is
part of the circuit involved in the control of eye
movements and other voluntary movements.
All nerve fibres to and from the body run
through the brainstem.
The substance of the mind
The Latin word “cortex” means bark. In the brain,
the cortex designates the grey matter, rich in
neurons, covering the outer surface of the brain.
These cells form a dense network of links to
adjacent cells within the same layer and to
deeper white matter cells. The cortex surface is
delineated into specialized areas for sensory
input and motor output which are well mapped.
Sensory fibres convey sensory impulses from all
parts of the body, in particular from the sensory
organs, to the brain. The motor fibres send
impulses from the brain to all the muscles of
the body.
The cortex is the seat of consciousness; sensory
and motoric impulses passing through the
cortex give rise to mental experiences.
Below the cortex, numerous nerve centres
(nuclei) control vegetative life of which we are
unconscious. These sensory and motor impulses,
which bypass the cortex and therefore escape
consciousness, include many automatic
movements, such as those that command the
position of the eyes, coordinate movement, or
control balance. Some of these automatisms,
such as reflexes, are inborn. Others are first
learned in the cortex and then transferred to
other deeper areas of the brain. Learning to
walk, ride a bicycle, or play the piano are
initially cortical functions. As cortical control
decreases, these activities become unconscious.
Here conscious control would be more of a
hindrance than a help.
Cardiovascular and
respiratory control are
seated in the base of
the brain where the
brain meets the spinal
cord. Here a collection
of nuclei called the
reticular formation
receive input from most
of the body’s sensory
systems (sight, smell,
taste, hearing, touch)
and other major structures
of the brain, such
as the cerebellum and
cerebral hemispheres.
Through links to motor
neurons passing
through the spinal cord,
the reticular formation
influences functions
such as cardiovascular
and respiratory rate,
based on the perceptions
received by the
The brain
Hjernen
sensory organs and interpreted by the brain.
The fibres ascending from the reticular formation
to the higher regions of the brain form a
network called the reticular activating system,
which influences wakefulness, overall degree of
arousal and level of consciousness – all functions
that are impaired in disorders such as depression
and anxiety.
The geography of memory
Memory, emotional experience and expression
are controlled by the limbic system. This system
The brain and its functions, diseases and disorders
are the basis for Lundbeck’s activities. Lundbeck
focuses solely on developing, manufacturing and
marketing drugs for treatment of diseases and
disorders of the central nervous system. Commonly
known as CNS disorders, they include psychiatric
disorders and neurological diseases.
Psychiatric disorders include depression, schizophrenia
and psychoses, and are caused by
disturbances or chemical imbalances in the
brain. Neurological diseases include Alzheimer’s
disease and Parkinson’s disease. Neurological
diseases are caused by conditions in the brain
which, over a period of time, gradually undermine
and destroy cells, causing serious health problems
for patients.
The brain can also be stricken by other pathological
conditions, such as brain haemorrhage or
stroke, which are caused by a thrombosis. A thrombosis
prevents vital oxygen from reaching the
brain cells, and generally has major physical,
motor and psychological consequences for
patients.
is not a structure, but a series of nerve pathways
incorporating structures deep within the brain,
such as the hippocampus and the amygdala.
These connections between the cortex, white
matter and other parts of the brain allow the
control and expression of mood and emotion,
the processing and retention of recent memory,
and the control of appetite and emotional
responses to food. All these functions are
frequently affected in depression, and the limbic
system has been implicated in the pathogenesis
of depression and other disorders, such as anxiety.
The limbic system is also linked with hormonal
control in the body, hence the notion that
depression is, at least in part, also a physical
disease.
Networking - making connections
The primary functional unit of the brain is a
cell called the neuron. All sensations, movements,
thoughts, memories, and feelings are

7
the result of signals that pass through neurons.
Neurons consist of three parts. The cell body
contains the nucleus, where most of the molecules
that the neuron needs to survive and
function are manufactured. Dendrites extend
out from the cell body like the branches of a
tree and receive messages from other neurons.
Signals then pass from the dendrites through
the cell body and down an axon and are sent
to another neuron,
such as a muscle
cell, or cells in other
organs. Neuronal
axons may be very
short, such as those
that carry signals
from one cell in the
cortex to another
cell less than a hair’s
width away. Axons
may also be very
long, such as those
that carry messages
from the brain
down into the spinal
cord. Most neurons
have many
dendrites, but only
one axon.
Scientists have
learned a great deal
about neurons by
studying the synapse
– the place where a
signal passes from
one neuron to another. When the signal reaches
the end of the axon, it stimulates tiny sacs or
vesicles. These vesicles release chemicals
(neurotransmitters) into the synapse. The
neurotransmitters cross the synapse and attach
to receptors on the neighbouring cell which in
turn can change the properties of the receiving
cell. If the receiving cell is also a neuron, the
signal can continue the transmission to the
next cell.
Some key neurotransmitters
Acetylcholine is called an excitatory neurotransmitter
because it generally makes cells more
excitable. It governs muscle contractions and
causes glands to secrete hormones. Alzheimer’s
disease, which initially affects memory formation,
is associated with a shortage of acetylcholine.
GABA (gamma-aminobutyric acid) is called an
inhibitory neurotransmitter, as it tends to make
cells less excitable. It helps control muscle
activity and is an important part of the visual
system. Drugs that increase GABA levels in
the brain are used for sedation and to treat
epileptic seizures and tremors in patients with
Huntington’s disease.
Serotonin is an inhibitory neurotransmitter that
constricts blood vessels and brings on sleep. It is
also involved in temperature
regulation.
Serotonin decrease in
the synaptic cleft has a
prominent association
with depression and
anxiety disorders.
The pharmacological
function of many antidepressants
includes the ability to enhance the
serotonin levels in the synapse.
Dopamine is an inhibitory neurotransmitter
involved in mood and the control of complex
movements. The loss of dopamine activity in
some portions of the brain leads to the muscular
rigidity of Parkinson’s disease. Psychosis can be
attributed largely to overactivity of dopamine.
Many medications, such as most antipsychotics,
work by modifying the action of dopamine
in the brain.
The matter of the mind
Modern science still attempts to link the biology
of the brain to mind and consciousness. We
now accept that thoughts, feelings and all other
manifestations of the mind and consciousness
are products of the activities of neurons in the
brain. Today, it is indisputable that no manifestation
of consciousness is possible without
the normal functioning of cerebral neurons.
Let this functioning be impaired by lack of
oxygen, or by a drug or trauma, and loss of
consciousness inevitably follows. However,
this concept of thought is not new. The same
theory was proposed two centuries ago.
“The brain secretes thought as the liver secretes
bile,” declared the eighteenth-century French
physician Pierre Jean Georges Cabanis (1757-
1808). In the climate of the times, these affirmations
were meant as provocative attacks on
religious belief in an immortal soul.
But even before Cabanis, one of the fathers of
medicine, Descartes (1596-1650) was the first
to raise the dualism of the body and the mind.
”From the brain and the brain alone arise
our pleasures, joys, laughter and jests,
as well as our sorrows, pains and griefs.”
He suggested that the human body and brain
were purely mechanical. The mind controlled
the body, but the body could also influence
the otherwise rational mind, as when people
act out of passion. His question of how a
non-material mind can influence a material
body remains an enigma today. The human
brain is the crown jewel of the human body,
humanity and this Earth’s evolution; giving us
thought, humanity, mind and soul.
Based on:
Science Week
Current Biology
Lundbeck Brain Atlas
Hippocrates (460-377 BC)

8
The Lundbeck Magazine 2007
Research and development of new drugs are the foundation for Lundbeck’s activities
innovative
drugs
In the 1950s and 1960s, Lundbeck was among the pioneers in developing medicine for
treatment of schizophrenia and depression. During this period, it became possible for
the first time to offer effective pharmaceutical treatment to patients with psychiatric
disorders. Lundbeck has since become a specialist in this area, and during the last 10
years its research activities have also focused on neurological diseases.
Despite many years of intense
research, drugs for treatment
of psychiatric and neurological
illnesses still offer primarily
symptomatic treatment. The
fact that no one knows with certainty why
these disorders arise is a major challenge.
However, during recent years, scientists have
come closer to understanding the biological
causes of these illnesses and, with time, this
knowledge will pave the way for new and
improved drugs.
Drugs of the future
Expectations to drugs will in future be different
than they are today. Lundbeck scientists are
therefore experimenting along the peripheries
of current knowledge. At present, Lundbeck has
research and development projects in the fields
of depression, schizophrenia, stroke, Parkinson’s
disease, Alzheimer’s disease, epilepsy and
alcohol dependence.
Stroke
Stroke is the third most common cause of death
in the industrialized world, exceeded only by
heart disease and cancer. At present, there is a
major unmet need for treatment of stroke and
its serious long-term disabling consequences.
Lundbeck is currently developing desmoteplase
for treatment of stroke. It is expected that

9
Azilect® (rasagiline) for the treatment of Parkinson’s disease was developed in collaboration
with Teva Pharmaceutical Industries Ltd. and launched in the first market in Europe in 2005.
According to the WHO five million cases of Parkinson’s disease are reported every year.
Cipralex® (escitalopram) is one of the world’s leading pharmaceuticals to treat depression
and anxiety. Cipralex® was invented by Lundbeck in 1988, launched in 2002, and is currently
marketed globally by Lundbeck and its partners. In the USA, Cipralex® is marketed under the
Lexapro® brand by Lundbeck’s partner of many years, Forest Laboratories, Inc. According to the
WHO 154 million cases of depression are reported every year.
desmoteplase can be given all the way up to
nine hours following a stroke. This will enable a
considerably greater number of patients to be
treated in comparison with today, where some
98 per cent of patients never receive pharmaceutical
treatment.
Ebixa® (memantine) for the treatment of moderate to severe Alzheimer’s disease is marketed in cooperation
with Lundbeck’s partner Merz Pharmaceuticals GmbH and was launched in 2002. According to
the WHO 23 million cases of Alzheimer’s disease and other dementia are reported every year.
Serdolect® (sertindole) for the treatment of schizophrenia was invented and developed by
Lundbeck and belongs to the group of so-called atypical antipsychotics, which is the latest generation
of pharmaceuticals used in the treatment of schizophrenia. According to the WHO 25 million cases
of schizophrenia are reported every year.
Schizophrenia
Lundbeck is currently developing several new
drugs for treatment of schizophrenia. Despite the
existence of numerous drugs for treatment of
schizophrenia, optimal treatment is still a long
way off. The fact that the disorder manifests itself
in multiple symptoms is a significant challenge.
The concept that one drug cannot cover all areas
of the brain is gradually being accepted, and
future drugs will to a greater extent be targeted
towards use in treatment with other drugs.
Depression
Depression is the most widespread disorder of
the central nervous system. For a number of
years, Lundbeck has been among the leaders in
the development of drugs for treatment of
depression. Today, it is possible to ease depression
symptoms in most patients who have the
disorder, so they can live a normal life. The aim of
future treatment of depression is to ensure faster
onset of action, and to help patients who do not
benefit from the current antidepressants.
Alcohol dependence
It is estimated that between five and six per cent
of the population in the United States, Europe
and Japan are dependent on alcohol, with major
health and social problems as the result. Current
treatment of alcohol dependence requires total
cessation of alcohol consumption, which is very
difficult for most people. Lundbeck has a new
substance known as nalmefene in clinical trials
for treatment of alcohol dependence. The
substance helps reduce excessive consumption
of alcohol, and thus holds out the prospect of
offering an entirely new form of help for alcohol
dependence.

10
The Lundbeck Magazine 2007
How we work in Lundbeck
From idea
to drug
Distribution of drugs
Lundbeck drugs are registered in more than 90 countries.
Lundbeck’s own representatives are in charge of spreading the
knowledge of Lundbeck products in 58 countries. As Lundbeck
products are prescription drugs, doctors must decide when
patients will benefit from them. Lundbeck spreads knowledge
of its products through publications in scientific journals,
participation in scientific conferences, and through meetings
with doctors and specialists.
Production of drugs
A drug must be safe and efficacious. It must also be possible to
produce it in large amounts and in a manner that enables patients
to take the drug and assimilate it optimally in the body. Lundbeck
manufactures its own drugs in Denmark, England and Italy where a
total of 956 persons are employed in the Production. Lundbeck also
collaborates with a number of other companies on various phases
of the production process, ranging from supply of raw materials and
semi-finished products, to pharmaceutical production and packing
of the drugs.

11
700 million in the world
According to the World Health Organization (WHO), more than 700 million cases
of disorders of the central nervous system are reported each year. These are serious
and life-threatening illnesses that affect not only patients’ quality of life, but also
that of their families and friends. For society in general, the major economic
consequences caused by these conditions make it important to develop new and
innovative drugs. During the past 50 years, novel drugs have revolutionized the
possibilities of treatment. However, there is still a huge unmet need for new and
innovative drugs.
From idea to drug candidate
Four hundred ninety-seven persons are employed at the Lundbeck
research units in Denmark and the United States. The basis for a new
and innovative drug is deep insight into the disorder itself, and into
the unmet needs of patients. The process takes between three and
five years, during which researchers work to identify where in the
human organism a new drug must act, and to test substances for
any efficacy, side effects and toxicity. If a substance passes all of
these tests, it becomes a drug candidate.
From candidate to approved drug
Lundbeck has development activities in some 40 countries around
the world. Approximately 650 employees are involved in development
activities which are necessary for a drug to be approved.
First, a substance is tested in healthy persons for its tolerability,
assimilation and distribution in the body. Following this, its efficacy
and side-effect profiles are tested in a small group of patients.
In the third and decisive phase, the drug is tested in a large group of
patients. Developing a new drug is very demanding, and normally
takes between eight and ten years.

12
The Lundbeck Magazine 2007
Chronic psychosis
Hard choices
My name is Marianne, and I live in Denmark. For 13 years, I have lived with a man who
was diagnosed as chronically psychotic about two years ago. I am very much in love
with him, but it is not an easy life, and it is necessary for us to live apart much of the
time. We have also decided not to have children.
Iwas 24 when I met him the first time.
I remember thinking that he was strange
– very noisy and loud-mouthed. It scared
me a little. I fell in love with him, but I
didn’t dare commit myself. He declared
his love for me, but I just didn’t dare.
I met him again five years later. I was then 29,
and we began living together right away. He
didn’t frighten me any more – perhaps because
I was more mature – but also because he had
changed. He was a social worker, a broadshouldered
and warm-hearted man who
inspired confidence. He was very loving. He is
the love of my life.
He was well at the time, but there was a loudmouthed
side to him that normally surfaced
when there were a lot of people. He wanted to
be the centre of attention.
Megalomania and paranoia
I cannot remember when he became ill, but it
began about two years after we met. In the
beginning, I actually thought there was something
wrong with me. And because I thought
there was something wrong in our relationship,
I went to a psychologist. My husband was
always very loud when we were with others.
He would talk relentlessly, shout and humiliate
me. He was very self-assertive, bragged a lot
and told everyone how great he was. At the
same time, he also felt that he was being
victimized by well-known people because of
his exceptional abilities. He was convinced that
everyone knew about him because he was so
intelligent. This was how his megalomania and
paranoia manifested itself.
I thought there was something wrong with
me because I couldn’t take his self-assertion,
but when the psychologist pointed out the
real problem, I began noticing what actually
happened.
Ill?
Not me!
My husband’s family refused to believe that
anything was wrong – until he was admitted
to a locked ward.
His paranoia got worse. He did things like
locking us in the bathroom and turning up the
radio to full volume, so ‘they’ couldn’t find us.
The day it got really bad, we had gone to
celebrate my mother’s birthday. My husband
saw ‘little blue men’ everywhere. The imaginary
companions were also there. My brother said,
‘we’ll take care of this,’ and a doctor came for
the first time. But he didn’t put my husband
into hospital, because my husband talked his
way out of it. But he got worse and worse. He
worked like mad. He had two jobs; it was as if
he shielded himself by working so much. But
as his paranoia increased, it gradually became
more difficult to control. His megalomania
made him feel far superior to everyone else; he
was both better and grander. He had absolutely
no problem whatsoever – and I couldn’t get
any professional help. He had to request help
himself, but he could not admit that he needed
treatment.
But we took a long summer holiday where we
fished, talked, relaxed and enjoyed ourselves,
and it seemed that the psychosis lifted and
went away by itself. However, the exceptional
individual with prospects of great wealth
became more and more a part of his personality.
He was no longer able to sleep at night. He kept
me and our neighbours awake for months by
playing very loud music. He ended up running
about in the streets and screaming while ‘eluding
his pursuers’. Finally, he became disinterested
in his life and did strange things in the traffic.
And then he was put into hospital; he could no
longer conceal his condition.

14
The Lundbeck Magazine 2007

15
Chronic psychosis
Committed to hospital
My father-in-law helped commit him to hospital
and took responsibility for it, to avoid strain on
my husband’s and my relationship. It is the worst
day of my life; it was horrible. I visited him every
day; I spoke with the personnel; I wrote letters
to them explaining who he was and giving
them information about his values and all the
symptoms.
Because he had been committed to hospital,
we had to wait three weeks for him to be given
medication. When he began taking medicine,
he got well in three days and was discharged. I
asked the hospital to keep him until he admitted
that he was ill, but they didn’t.
It was fantastic how quickly he got well. It is
rare to find the right medicine the first time.
But he didn’t take it when he came home
again. There wasn’t anything wrong with him.
He had a good employer, so he was able to go
back to work, but it didn’t last. During the
course of 18 months, he was committed to
hospital four times. By then, I was adamant:
when he gets ill, he goes to hospital.
The fourth time he was admitted, he asked me,
‘What can I do so this doesn’t happen again?’
‘You only need to take your medicine,’ I replied.
He now knows his disorder well enough so he
can tell when it is coming on. He feels restless
and can’t sleep. He says that he can ‘feel’ his
brain. Then he takes his medicine voluntarily. But
he also medicates himself as he thinks best.
Some days he takes a double dose, other days a
half dose, and some days nothing at all. He is
forever trying to quit his medicine. But at least
he hasn’t been in hospital for five years. He
doesn’t have a second personality either, and his
persecutors have disappeared. But we still have
to live with his megalomania and his paranoia.
His former self
After his last stay in hospital, he made a
decision; he wanted to know what to do to
recover his life. Consequently, he finally agreed
to register for treatment with the community
psychiatric services. Since then, he has slowly
returned to being his former self.
My many roles
His diagnosis is chronic psychosis – and most
of the time he does very well. But if he drinks
alcohol, things go wrong. Then I am the diplomat
who smoothes things out, explains, and defends
him. I am always in a state of alert; always
ready to come sliding down the fireman’s pole
to his rescue. When he is ill, I am his ambulance
service and nurse; at that point we are no
I am always in a state of alert; always ready to come
sliding down the fireman’s pole to his rescue. When he
is ill, I am his ambulance service and nurse; at that point
we are no longer a couple.
longer a couple. I take on a maternal role. That
is not an appropriate role in a relationship. We
are in a relationship, but still not really – not
always, anyway.
After several years, I took a room in another
part of town so I had a place to go when he
wasn’t well. Now, we have instead bought a
summer cottage which is his. We need an extra
place of refuge. He spends a lot of time in his
summer cottage.
Having a husband with a psychiatric disorder is
expensive. His income depends on mine, and
we need to have two homes. We are together
when it’s possible, but we live apart half of the
time.
Room for me
There is room for me in my life. I have several
girlfriends whom I have known during the
entire process. I once asked if there were any
support groups for husbands and wives, but
was told that there are none. Spouses do not
remain in that kind of marriage or relationship.
The only ones who stay are mothers, because
they cannot leave. But one of my colleagues
understood my situation; her husband was also
ill. And two other girlfriends had had similar
experiences. They taught me to laugh at it –
you have to laugh to survive.
However, I have made many difficult choices.
It is not possible for me to work full-time.
Therefore, I decided to be self-employed. It is
good to be able to plan my own time. I left the
business I was in – a managerial post and a career
with the possibility of earning a high salary.
Today I am a freelancer on our own terms. My
husband’s disorder has cost me an international
career, and we have not had the family we
might have had. It is a decision we have made,
but it was not easy.
A calm and quiet life
Life is wonderful when he is well. One has a
different perception of happiness when one
actually has to live with a psychiatric disorder.
Our life together functions now – when we
organize it to ensure that there is no stress or
strain. There must not be anything impulsive,
except for things which are under our control.
We must plan our life – and keep to our plans.
He spoils me, and we have many good meals
with our friends because he is a good shopper
and a good cook.
Openness about the disorder
Our story is not a long tale of pain and
suffering. My husband and I are very close-knit.
We have confidence in each other and we give
each other freedom; this makes our relationship
worthwhile. We have chosen to be open
about our situation. Everyone who knows my
husband knows that he has a psychiatric
disorder. He tells his story when he meets
his old friends: he has a disorder, but it is now
under control.

16
The Lundbeck Magazine 2007
Parkinson’s disease
The world did not
come to an end
My name is Hans-Jürgen Cosmo. I was diagnosed with Parkinson’s disease in 1996 when
I was 56 years old. I am a mechanical engineer, and was at the time working as factory
manager for a multimedia company in Hanover, Germany.
The factory produced plastic components
for televisions. In 1996, I had
been assigned the job of moving the
company’s production activities and
making 250 employees redundant
by 1998, and was consequently under a great deal
of pressure. When my right toe began trembling
uncontrollably, the first thing I thought of was stress.
The symptoms surprised my orthopaedist who said
that he had never seen a toe like that before, and
referred me to a neurologist. I was sent to a neurology
clinic where the first doctor said that I was far
too young for the problem to be Parkinson’s. The
next doctor recommended stress therapy. However,
autogenic training – a form of relaxation therapy
– only made my resting tremor worse. After
my third or fourth appointment, the doctor asked
me to walk back and forth in front of him. That
made it obvious – limp right arm, small steps: clear
signs of Parkinson’s disease.
‘And what is that?’ was my first thought. I had
never before been in close contact with Parkinson’s.
The book the doctor gave me to take home was a
horror scenario. My wife immediately put it aside.
Mrs Cosmo, who is the same age as her husband,
adds, “The book only stated how bad Parkinson’s
can become; that my husband would soon be in a
wheelchair; that he would soon be unable to speak
and express himself. It was definitely not the
kind of information I needed. At the clinic that
prescribed my husband’s medication, the
psychologist agreed with me completely.”
“The L-dopa test confirmed that I had Parkinson’s,”
Hans-Jürgen Cosmo continues. “At first I felt really
low, but then I began gathering information and
adjusting to the idea of living with the disease. I
informed my colleagues, gave them an information
brochure, and continued working. I was entirely
open about my condition, and the company did
not treat it as a problem. The management backed
me up, and I was able to continue working for two
years until the factory closed. I joined the German
Parkinson’s Association at once, and asked to be
given something to do.
Today, I am the national representative of the German
state of Niedersachsen, which means that I
organize meetings, invite speakers, and things like
that. My Parkinson’s, which is dominated by tremors,
has progressed very slowly, so I have been fortunate
in that my honeymoon period* lasted for
more than 11 years. When my medicine works, I
hardly notice any effects of the disease at all. But
the medicine doesn’t work as long as it used to.”
The diagnosis also came as a shock to Christa, Hans-
Jürgen’s wife. “I had no suspicion whatsoever that
anything was wrong. It causes major changes in your
daily life, especially now that the tablets no longer
have the same effect. Sometimes he simply freezes
and cannot move. He is afraid of falling, so I usually
accompany him when he goes anywhere. It’s not
what I thought our retirement would be like. It’s a big
strain, but one gets used to it.”
“One has to accept the diagnosis and accommodate
one’s Parkinson’s friend,” Hans-Jürgen points out
emphatically.
“The world doesn’t come to an end, just because
things don’t always go so well,” Christa says. “So, we
change our plans and adapt them to what is possible.
There are only the two of us; our son has had his own
home for a long time, now; he is a computer scientist
in Nuremberg.”
New ways
“One doesn’t die from Parkinson’s and one’s brain
remains clear,” Hans-Jürgen Cosmos states. “But one
speaks with less volume and doesn’t answer quite
as quickly. It’s necessary to be patient when speaking
with people who have Parkinson’s, and avoid answering
for them. I made that mistake at first myself.”
*The period during which Levodopa treatment works well
without side effects is known as the honeymoon period.

18
The Lundbeck Magazine 2007

19
Still a mystery
The causes of
depression
My name is Connie Sánchez, and I am a pharmacist. Since 1981, I have worked
with developing drugs for CNS disorders, primarily antidepressants.
I
am a pharmacist and have a doctorate in
pharmacology. My training as a pharmacist
provides a broad basis for understanding
how drugs act in the body and also how
drugs are produced in practice.
At present, we are working with a jigsaw puzzle
– to create a new breakthrough in treatment of
depression, we must find the biological cause –
or causes – of depression. We must understand
the biology behind the disorder to acquire new
‘handles’ to the mechanisms we must influence
to make patients well.
Quiet in the wards
In 1981, I began working at Lundbeck with
clinical research and development of drugs for
psychiatric disorders. I did not know a great deal
about these disorders, but I was interested in
learning about them – and also fortunate
enough to be tutored by a retired chief physician
in psychiatry. He was a man with very comprehensive
experience, having practised psychiatry
before efficacious medicines were available.
I remember him telling me how quiet the
wards became once medicine was available for
treatment, and also that many patients were
subsequently able to resume their normal lives.
Relatively quickly I began working with the
substance citalopram for the treatment of
depression. I worked with clinical reports, but
after a couple of years I decided to become a
research pharmacologist because I wanted to
be the person who propelled research projects
forward during their early phases.
Still a mystery
Although depression has been described since
ancient times, we still do not know what causes
the disorder. We know that it is, to some extent,
hereditary, and we know likewise that it is
partially related to environment and stress. Yet,
despite having worked with the disorder for
many years, we still do not know exactly what
provokes it, though it appears to be an interaction
between several factors.
Chemical reactions
In all simplicity, depression is a question of
chemical reactions. It is an expression of how
brain structures communicate.
Up to now, the best treatment for depression
has been the selective serotonin reuptake
inhibitors (SSRIs). In depression, the serotonin
level in the brain is low. The SSRIs raise the
serotonin level to normal, after which the
depression lifts.
I have participated in documenting that the
separation of two molecules – the S and R
enantiomers – resulted in a new and far more
effective antidepressant. Separation gives the
one enantiomer a double effect, enabling it to
raise the serotonin level even faster. This leads
to faster recovery, and is an outstanding
improvement in modern antidepressants.
A vicious circle
Depression is a cyclical disorder. In other words,
untreated depression will sooner or later lift
and leave the patient well – in any case, until
it returns. The worse a depression is, the longer
it takes to lift and the greater the likelihood of
relapse.
The antidepressants which are currently
available – and this is true of all antidepressants
– do not cure the disorder. They help
nature on its way so the patient improves
faster, but there is still the risk of depression
returning. It would thus be very beneficial if we
could develop a medicine that can break the
vicious circle of depression.

20
The Lundbeck Magazine 2007
Still a mystery
At Lundbeck, a total of 497 scientists at the
Danish and American research units are working
to discover and develop drugs for treatment of
psychiatric and neurological diseases.
Depression is the most widespread CNS disorder.
The disorder varies in strength from mild depression
to long-term invalidity and a life-threatening
depressive state. Depression strikes all age groups,
and the WHO estimates that there are approximately
154 million persons around the world
who have depression requiring treatment.
I have participated in documenting that the
separation of two molecules – the S and R
enantiomers –resulted in a new and far more
effective antidepressant.
Biological causes
One reason why it is so difficult to tackle the
biological cause of depression is that a depressed
cell cannot be removed and examined like one
can do with cancer cells, bacteria and viruses.
Our work with depression is based on subjective
observations or, in other words, on diagnoses
based on the symptoms that can be observed.
Our greatest ambition is to define depression as
a disorder with a biological cause that can be
treated. When we achieve that, we will probably
be able to develop a substance that can break
the vicious circle of depression.
people is a fantastic opportunity. It is a huge
satisfaction for a scientist to experience
that some of the work one has done
can be used – that it really can
help sick people get well. The
greatest joy for a researcher is to
see the molecule one has worked
with be distributed and help a
lot of people.
From Denmark to the USA
Two years ago my family and I moved
to the US so I could continue my
research at Lundbeck’s American
research unit. It is an interesting task.
The American pharmaceuticals market is
the largest in the world. Being where the
molecules we invent will be used by the most

21
Partnerships
Lundbeck
and partners
Seen in an international perspective, Lundbeck is a small pharmaceutical company among
large multinationals. For this reason, Lundbeck has for many years been entering into
partnerships and agreements with other companies to obtain access to expertise and
resources which are important in both research and commercialization of drugs.
Developing and marketing new
drugs is both complex and
costly. At the same time, the
period during which the
expenses involved can be recovered
is continually becoming shorter. In order
to maintain the strongest possible position
despite these challenges, Lundbeck has for
many years developed and commercialized
drugs in fruitful collaboration with other biotechnology
and pharmaceutical companies.
Partnerships enable Lundbeck to exchange
knowledge and to develop new drugs in cooperation
with other companies. We receive
financial as well as knowledge resources.
Colla-borating with partners has made it
possible to increase the number of research
projects, and thus the probability of success.
Thanks to many years of targeted efforts in
this area, Lundbeck can offer its partners highly
specialized knowledge in CNS research in return,
and many consider Lundbeck to be a very
attractive partner.
Among the partners Lundbeck collaborates
with in development of new drugs are:
Solvay Pharmaceuticals B.V. on development
of the antipsychotic bifeprunox.
Paion AG on development of desmoteplase
for stroke.
BioTie Therapies Corp. on development of
nalmefene for treatment of disorders such as
alcohol dependence.
Lundbeck also collaborates
on sales and marketing with:
Forest Laboratories, Inc. on sales and marketing
of Lexapro® in the United States.
Teva Pharmaceutical Industries Ltd. on sales
and marketing of the Parkinson’s drug Azilect®.
Merz Pharmaceuticals GmbH on sales and
marketing of the Alzheimer’s drug Ebixa®.

22
The Lundbeck Magazine 2007

23
South Korea a growing market
The key word
is development
My name is Pil Soo Oh, and I am the Managing Director of Lundbeck Korea where we have
40 employees. In 2006, we received the Best Korea Awards for pharmaceutical companies
in South Korea. During recent years, the market in Korea has grown due to economic
development as well as a greater openness regarding depression.
Ihave an engineering degree in metallurgy,
but I have never worked as an engineer.
Instead, I chose to have a career in the
pharmaceutical industry. Besides my
engineering degree, I have a master’s
degree in management from an American
University in Seoul.
Difficult conditions
The South Korean pharmaceuticals market is
the 12th largest in the world. Even though the
market share for treatment of psychiatric and
neurological disorders – which we collectively
call the CNS market – is growing rapidly, it is
still relatively small and underdeveloped.
Mental disorders are not given high priority in
Asian societies including South Korea, and there
are only limited funds and other resources for
treating them. Priority is instead given to more
obvious diseases such as cancer.
Greater openness
There are stigmas surrounding mental disorders
everywhere in the world, but in South Korea
they are very pronounced. Only a few years ago,
anyone here with depression would have tried to
conceal it at any price. However, this has begun
to change. When the son of a well-known
businessman committed suicide, it was stated
publicly that he had had depression. The situation
repeated itself when a very popular Korean film
actress recently committed suicide. No one
could understand why. These unfortunate situations
have led to a greater public understanding
of the disorder, and we have experienced greater
openness around depression during the last five
years.
Still, most people with depression consult
specialists in internal medicine rather than
psychiatrists. The patients focus on the physical
symptoms associated with depression, such as
insomnia or perhaps abdominal pain.
There are some 2500 psychiatrists in South Korea.
We cooperate closely with 300 of them who
play key roles in depression treatment in Korea.
Together with these specialists, we are working
to increase awareness of depression and to break
down the stigmas surrounding the disorder.
Lundbeck is a small actor in the South Korean
market, but we are establishing our reputation as
a valuable CNS partner. We work primarily with
the hospitals because Koreans prefer them to
clinics. They consider hospitals to be more
modern and to have better facilities. This means
that South Korean hospitals are often overcrowded.
The South Korean government has implemented
a campaign to convince patients that clinics offer
adequate treatment for minor problems.
Development
The key word in South Korea is development.
From being an agrarian society, the country has
experienced marked development and become
an industrial society with a strong economy.
Lundbeck Korea has experienced similar growth
during the five years we have been here.
Naturally, our success must be ascribed to our
employees. As Managing Director, I emphasize
the importance of personal as well as career
development. To keep people motivated, we
provide our staff with various opportunities for
professional development. We have therefore
introduced the concept of internal job posting.
This enables the individual staff member to
pursue a career with various options within
the company, even though we are only a small
organization.
Fifteen of our employees have administrative
functions and 25 are medical sales representatives.
Most of us have a natural science background and
many have attended graduate school.

24
The Lundbeck Magazine 2007
The LUNDBECK INSTITUTe
Education
as a passion
My name is André Joubert, and I am a psychiatrist. I am Director of Psychiatry and
Neurology at the Lundbeck Institute in Copenhagen. Since the seminars began in
1997, approximately 100,000 psychiatrists, neurologists and other mental health
care workers have directly or indirectly participated in our educational ‘cascade’.
The Lundbeck Institute is the only
institution in the world that
offers doctors and health care
professionals the opportunity
of sharing their knowledge
and learning from each other’s experience at
a week-long seminar. Many of our seminar
participants conduct workshops for their
colleagues when they return home.
In keeping with Lundbeck’s vision, the aim
of the Institute’s educational activities is to
improve the quality of life of persons who have
psychiatric and neurological disorders. In this
context, it is important to remember that
families and friends also need help, as the
illness of a close relative or friend also affects
their quality of life.
Recognizing patients’ needs
I grew up and completed my medical studies
in South Africa. I was invited to work at the
Lundbeck Institute nearly 10 years ago, on the
recommendation of the previous Managing
Director of Lundbeck South Africa. At the time,
I was a psychiatrist at a government hospital in
Bloemfontein. I had become interested in
psychiatry while working as a GP in South
Africa. As I spent time talking to my patients,
I became aware of their tremendous need for
understanding, support and hope in dealing
with their psychological and psychiatric problems.
I soon realized that I needed further
education. It was during my specialization as
a psychiatrist that I began teaching medical
students and discovered how rewarding this
was. The combination of my passion for
teaching and psychiatry eventually led me
to the Lundbeck Institute in Denmark.
Educational ‘cascade’
The Lundbeck Institute conducts 16 one-week
seminars annually at the Institute north of
Copenhagen. The seminar topics are schizophrenia,
mood disorders and anxiety, as well
as dementia and depression in the elderly. Each
seminar is attended by five or six persons from
five different countries – between 25 and 30
participants per seminar. The participants work
in groups with one person from each country
per group. This enables participants to learn
from each other’s experience with an international
perspective.
The seminar participants are predominantly
psychiatrists, but also neurologists and geriatricians.
Participants have a wide range of experience
in medicine due to large differences in
education and in the number of years they
have been treating patients. There are also
major cultural differences among these doctors.
These differences include their cultural perception
and tolerance regarding psychiatric disorders,
stigma and the nature of the doctor-patient
relationship in their individual cultures. In some
cultures, doctors are highly respected and seen
as leaders. Their advice is followed strictly and
they are seldom contradicted or even questioned
by the patient or relatives. In many other cultures,
the role of the doctor has changed considerably
and patients often seek help elsewhere or get
second opinions. There are also cultural differences
with regard to the types of treatment
offered and accepted in society, and therefore
there are large differences in the actual treatment
provided.
One of the remarks most commonly made
after seminars is how much participants have
appreciated the differences between the various
countries and doctors present, as this enriches
the discussions. These differences in perceptions
and treatments provided to patients are
good starting points for discussions on international
treatment guidelines, and on available
treatment options for the optimal management
of patients.

26
The Lundbeck Magazine 2007
the LUNDBECK INSTITUTe
The World Health Organization (WHO) estimates
that only half of the patients with mental disorders
are detected. Awareness and early identification are
of utmost importance.
Following our seminars in Denmark, participants
have access to all our educational materials,
which enables them to arrange similar educational
activities for colleagues in their home
countries. The aim is for the participants to
spread their knowledge and experience to as
many people as possible. This is what we call
the ‘educational-cascade’ model.
Besides the seminars in Denmark, the Institute
also organizes seminars in other countries, and
many Lundbeck subsidiaries around the world
conduct their own workshops which are based
on the Institute’s concept. The Institute also
participates in congresses and symposia, often
presenting workshops.
The Lundbeck Institute currently has an associate
faculty of 92 specialists in psychiatry and
neurology. The faculty members write and
review our educational materials and are our
guarantee of a high scientific standard. During
the 10 years we have been working with our
educational programme, we have had nearly
3000 specialists at the Institute in Denmark, and
they in turn have provided follow-up training
for approximately 100,000 mental health care
professionals around the world.
Internet support for
patients and relatives
The Institute provides education for patients
and relatives on the Internet. The first site
we developed is DepNet, a site providing
depression information and support to patients
and their relatives, www.DepNet.com. The site
has been adapted to various countries’ needs
and cultural differences, and now operates in
more than 14 countries. In 2005, we started a
similar site for persons with dementia and their
relatives, www.DementiaNet.com.
These sites provide extensive information on
depression and dementia, and further assistance
is available through a panel of experts
who answer questions posted to them. The
answers are often, with the permission of the
user asking the question, posted on the website
so that other users can learn more about these
illnesses.
Five major CNS organizations are represented on
the Lundbeck International Neuroscience Foundation
board.
• World Psychiatric Association (WPA)
• Collegium Internationale Neuropsychopharmacology
(CINP)
• Association of European Psychiatrists (AEP)
• European Federation of Neurological Societies (EFNS)
• European Collegium Neuropsychopharmacology (ECNP)
The key role of the board is to be the strategic decisionmaker
for the Lundbeck Institute and to ensure that
Lundbeck Institute activities are objective and of the
highest standard.

27
The Lundbeck Foundation
DKK 248 million
to research
With approximately 70 per cent of the company’s shares, the Lundbeck Foundation is
the principal shareholder of H. Lundbeck A/S. The foundation was established in 1954
by Grete Lundbeck, Hans Lundbeck’s widow, and is today one of the largest private
contributors to natural science research in Denmark.
The Lundbeck Foundation was
founded to safeguard and
expand the activities of the
Lundbeck group, and to
contribute financial support to
high-quality research in the natural sciences.
Lundbeck was listed on the Copenhagen stock
exchange in 1999, resulting in the Lundbeck
Foundation since having additional funds to
distribute as grants and support for research
and scientific activities in Denmark, as well
as to Danish scientists abroad.
The Lundbeck Foundation made donations of
DKK 248 million in 2006, and expects to
donate approximately DKK 285 million in
2007. Donations are made with no conditions
concerning rights or confidentiality of research
results. The foundation attaches great importance
to research results being freely accessible.
The primary aim is to support natural science
research of the highest international standard.
Donations from the foundation are made on
the recommendation of a scientific committee.
The committee has eight members.
Funds are given to scientists and projects in
Denmark, or to Danish scientists working
abroad. The Lundbeck Foundation also awards a
number of research prizes every year, including
the Nordic Scientist Prize, a prize to a young
scientist, and a number of talent prizes. Each
year, the Lundbeck Foundation also grants a
number of five-year professorships. There are
currently Lundbeck professorships at Rigshospitalet
in Copenhagen, the University of Southern
Denmark in Odense, and the Technical University
of Denmark in Copenhagen, as well as a
professorship in clinical nursing and one in
experimental studies of human virus and viral
infections.

28
The Lundbeck Magazine 2007
In dialogue with Lundbeck’s suppliers
Healthy and safe
environment
Lundbeck suppliers must not only comply with Lundbeck quality criteria, but also with
basic principles concerning conditions for employees, environmental responsibility,
and a safe work environment. These principles have been taken from the UN Charter
of Human Rights and the UN International Labour Organization.
M
y name is Camilla Ransfort.
I have a master’s degree in
technical and social sciences,
and I am head of section in
the Health and Safety
Department. My job is to ensure that Lundbeck’s
employees work under conditions that promote
their health and safety. One year ago, I became
manager of a project that is also to ensure
the health and safety of the employees of
Lundbeck’s sub-suppliers around the world.
Environmental health and safety are very close
to my heart, and it is a real pleasure to help
make a difference in countries that do not yet
have a tradition in this area.
By engaging our sub-suppliers in a dialogue on
how to observe basic environmental health and
safety regulations in the workplace, Lundbeck
can help protect the environment and ensure
that the employees of Lundbeck associates
around the world have a better work life.
Lundbeck’s mission is to help sick people get
well, and it is vital that people do not become
ill from manufacturing our products. We will
not operate a business at the expense of either
the natural environment or human health.
Basic rights
We have compiled a method for evaluating the
environmental health and safety of our subsuppliers,
as well as the working conditions of
their employees. In future, our suppliers will not
only have to comply with Lundbeck price and
quality requirements, they will also have to
meet, for example, standards that ensure that
work safety conditions are appropriate, that
employees’ right to be a member of a labour
union is respected, and that the company
causes as little stress as possible to the
surrounding natural environment.
Environmental audit in the Czech Republic
I have been in both India and China to audit
potential suppliers, and I was recently in the
Czech Republic to audit one of Lundbeck’s
major suppliers, the chemical manufacturer
Farmak whose 271 employees produce –
among other things – two active substances
for Lundbeck’s drugs.
The audit was a step in compiling the method
that in future will ensure that suppliers meet
not only Lundbeck’s quality standards, but also
basic standards for environmental responsibility
and work conditions.
Before a colleague and I went to Olomouc in the
south of the Czech Republic, we had sent the
company a questionnaire which they had
completed and returned to us. The questionnaire
deals with everything from the way a company
handles dangerous substances, to hourly wages
for their production workers. At the audit, we
review all the questions and ask to see documentation
of, for example, their measurement
of waste water discharges, so we can verify that
they remain within the limits allowed.
The objective is constructive dialogue, and I
attach great importance to maintaining a good
atmosphere during an audit. As we are interested
in having a good working relationship
with our suppliers, it is in our best interests to
help them move forward, if this is possible.
We aim to ensure that Lundbeck has robust
agreements and reliable supplies while, at the
same time, showing due consideration for the
environment and work conditions.
It is my experience that Lundbeck has good
and cooperative suppliers who understand the
reason for the standards we set, and therefore
are very cooperative. And that helps make my
job a real pleasure.

30
The Lundbeck Magazine 2007

31
From science to everyday life
Knowledge
obliges
My name is Theresa Branchek. I am a neurobiologist and Manager of Lundbeck Research
in the United States. We do research in the mechanisms of the brain to find substances
that can be developed into beneficial drugs. Besides my work, I am involved in a charitable
institution – known as Integrity House – that helps substance abusers.
As a neurobiologist, I have a deep
interest in brain functions – in
what happens in normal brain
function as well as in disease.
I I
I became interested in how the
brain works when I was just beginning my
university studies. I wanted to know what
happens when the brain is malfunctioning and
how drugs can affect various areas of the brain.
Originally, I thought I would have an academic
career, but my interest in drug research continued
to grow and I decided to join a biotech
company in New Jersey in 1989. Here, I became
a member of a team that studied brain
functions and drug targets which are significant
in many of the disorders that Lundbeck works
with, including depression and anxiety. In 2003,
Lundbeck acquired the company and we are
now part of the Lundbeck research organization.
Saves lives
I have been associated with Integrity House for
three years. Since its founding in 1968, Integrity
House has helped substance abusers in the
state of New Jersey to become and remain free
of substance abuse. As a ‘therapeutic community’,
Integrity offers its members an integrated
support programme that includes education,
job training, life skills training, medical assistance,
and other services.
I support Integrity House because the project
saves lives and strengthens the local community.
As a neurobiologist and adviser to the
National Institute of Health and the National
Institute of Drug Abuse, I know that substance
abuse is a medical condition rather than merely
a ‘lifestyle choice’ and that there is a big overlap
between psychiatric disorders and substance
abuse.
As Manager of Lundbeck Research USA, I am
involved because there is obvious synergy
between Lundbeck and Integrity House. Both
organizations strive to improve people’s quality
of life through effective treatment and by
preserving the integrity of the individual.
It could be you
In my childhood, I lived in an area where substance
abuse was common. I have seen friends
die and families destroyed by it. But I know
that no one plans a career as a substance
abuser. No one chooses to be an addict. There
are many social and financial issues in connection
with substance abuse, and offering methadone
treatment is not enough. The patients
need education, job-readiness programmes,
health outreach, and medical care.
I can be of service to Integrity House because
they need a knowledgeable advocate who can
discuss substance abuse from a technical and
scientific point of view.
Battle against prejudice
For many years, depression and other psychiatric
conditions have been surrounded by stigma.
Thanks to education and information about the
disorder, this stigma has been reduced, although
there is still significant room for education and
improvement in public perception. However,
there is also a great need to raise public awareness
to the fact that there is a physiological
reason why some individuals turn to substance
abuse; that there is a biological reason for their
disorder. We know from scientific studies that
substance abuse is caused by and/or maintained
by a dysfunction in the brain. I would like to help
reduce stigma for substance abuse and other
mental illnesses, and to help Lundbeck build
bridges between science and people’s everyday
lives.

32
The Lundbeck Magazine 2007
FROM 1915 TO THE PRESENT
LUNDBECK
MILESTONES
1915
14 August. Hans Lundbeck founds a
trading company in Copenhagen which
deals in everything from machinery,
biscuits, confectionery, artificial sweeteners,
aluminium foil, photography
paper, cameras and cinema equipment,
to Hoover (vacuum cleaner) rentals.
1920s
1924 Eduard Goldschmidt joins the
trading company and brings in suppositories
for haemorrhoids, painkillers,
etc. Colognes and creams are added to
the company portfolio.
1930s
1937 Lundbeck introduces its first
original drug Epicutan® for treatment
of wounds.
1939 Lundbeck moves to Ottiliavej in
Valby.
1940s
1940 Lundbeck introduces Lucosil® for
treatment of urinary infections.
1943 Hans Lundbeck dies. Poul Viggo
Petersen is employed. He initiates drug
research activities, creating Lundbeck’s
psychopharmaceutical niche.
1950s
1954 The Lundbeck Foundation is
established with Grete Lundbeck as
chairman.
1957 Lundbeck succeeds in
synthesizing Truxal®.
1959 Truxal® is marketed, followed by
Cisordinol® and Fluanxol® which have
been refined as sustained- release
drugs.
1960s
1961 Lundbeck purchases the former
creamery in Lumsås to acquire more
production capacity. Production of
active substances is soon in progress.
1967 The Lundbeck Foundation
purchases the shares owned by the
Goldschmidt family, making
it the sole owner of Lundbeck.
RUXAL ®

33
1990s
1996 Serdolect® is launched.
1970s
1972 Citalopram is synthesized.
1997 Lundbeck gets new logo. Designed
by Wolff Olins, the star becomes part
of the original Lundbeck logo that was
designed by the Hungarian-French artist
Victor Vasarely in the 1930s.
1975 Microbiological research ceases.
1975-80 The trading company and
cosmetics department are phased out.
1980s
1987 Erik Sprunk-Jansen becomes
President & CEO.
1980a Lundbeck defines CNS as its
overall strategy.
1989 Cipramil® is launched in
Denmark.
1998 Cipramil® is approved in the
United States under the name Celexa®,
and launched on the American market.
1998 Claus Bræstrup becomes
Executive Vice President of Research.
1998 Lundbeck voluntarily withdraws
Serdolect® in all countries, due to a
suspicion that it could cause serious
heart problems for a very small group of
persons with schizophrenia.
1999 Lundbeck is listed on the Copenhagen
Stock Exchange.
2000-06
2003 Lundbeck acquires the American
research company Synaptic, establishing
an American research unit as a
bridgehead in the United States.
2003 Claus Bræstrup succeeds Erik
Sprunk-Jansen as President & CEO.
2004 Lundbeck and the American
company Merck & Co. establish a
strategic partnership with a view to
marketing the soporific gaboxadol
2005 Azilect® (rasagiline) is launched
for treatment of Parkinson’s disease.
2005 The EMEA Committee for
Medicinal Products for Human Use
(CHMP) revokes suspension of
Serdolect®, whereby Lundbeck regains
the right to market the drug.
2005 Lundbeck enters into an
agreement with the German
biopharmaceutical company PAION
AG on development of the substance
desmoteplase for treatment
of stroke (blood clot in the brain).
2006 Serdolect® is re-launched first in
Estonia, followed by other countries.

34 The Lundbeck Magazine 2007
LUNDBECK
at a glance
Pharmaceuticals developed by Lundbeck have been used in more than 200 million
treatments. Lundbeck aims to continue to develop new and innovative pharmaceuticals
to help people who suffer from CNS diseases.
Lundbeck worldwide
More than 5,300 employees represent
Lundbeck in 58 countries.
n Research
n Production
n Sales

35
12.9%
2.9%
15.1%
14
By the end of 2006, Cipralex® held
a market share of 12.9 per cent in
Europe.
By the end of 2006, Azilect® held
a market share of 2.9 per cent in
Europe.
By the end of 2006, Ebixa® held
a market share of 15.1 per cent in
Europe.
Serdolect® was launched
in 14 markets in 2006.
Revenue DKK 9,221 million
Research and development costs DKK 1,958 million
Profit from operations DKK 1,784 million
Net profit for the year DKK 1,107 million
2006 figures
Development pipeline
In 2006, Lundbeck pursued for the clinical
development activities for the treatment of:
• Alcohol dependence
• Depression
• Mood disorders
• Schizophrenia and other psychotic disorders
• Sleep disorders
• Stroke

The specialist in psychiatry
and pioneer in neurology
H. Lundbeck A/S
Ottiliavej 9
2500 Copenhagen - Valby
Denmark
Corporate Reporting
Tel +45 36 30 13 11
Fax +45 36 30 19 40
information@lundbeck.com
www.lundbeck.com
CVR no. 56759913